ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 088,62
-0,16%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) Actualités

AZN

AstraZeneca (AZN)

AstraZeneca PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateHeureSourceTitreSymboleSociété
12/06/202423h35Business WireFARXIGA approved in the US for the treatment of pediatric type-2 diabetesNASDAQ:AZNAstraZeneca PLC
12/06/202416h14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
10/06/202413h00Business WireTAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancerNASDAQ:AZNAstraZeneca PLC
06/06/202413h00PR Newswire (US)I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical OfficerNASDAQ:AZNAstraZeneca PLC
04/06/202416h02Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:AZNAstraZeneca PLC
04/06/202415h10IH Market NewsEconomic Worries May Lead To Weakness On Wall StreetNASDAQ:AZNAstraZeneca PLC
04/06/202413h00PR Newswire (US)AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024NASDAQ:AZNAstraZeneca PLC
02/06/202420h32Business WireTAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trialNASDAQ:AZNAstraZeneca PLC
02/06/202414h05Business WireIMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placeboNASDAQ:AZNAstraZeneca PLC
02/06/202414h00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapyNASDAQ:AZNAstraZeneca PLC
28/05/202422h30GlobeNewswire Inc.Cellectis Reports Financial Results for First Quarter 2024NASDAQ:AZNAstraZeneca PLC
28/05/202415h06Business Wireダトポタマブ デルクステカン、 進行性非扁平上皮非小細胞肺癌患者に対する第III相TROPION-Lung01試験において、 化学療法と比較して臨床的に有意な全生存期間の改善を示すNASDAQ:AZNAstraZeneca PLC
27/05/202422h55Business WireDatopotamab-Deruxtecan zeigt in Phase-III-Studie TROPION-Lung01 klinisch signifikante Verbesserung des Gesamtüberlebens im Vergleich zur Chemotherapie bei Patienten mit fortgeschrittenem nicht squamösem, nicht kleinzelligem LungenkrebsNASDAQ:AZNAstraZeneca PLC
27/05/202419h14Business WireLe datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameuxNASDAQ:AZNAstraZeneca PLC
27/05/202413h00Business WireDatopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trialNASDAQ:AZNAstraZeneca PLC
23/05/202419h52Business WireAstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)NASDAQ:AZNAstraZeneca PLC
22/05/202413h00Business WireAstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​NASDAQ:AZNAstraZeneca PLC
22/05/202400h44Business Wireアストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定NASDAQ:AZNAstraZeneca PLC
21/05/202417h37Business WireAstraZeneca strebt für 2030 einen Gesamtumsatz von 80 Milliarden US-Dollar und ein nachhaltiges Wachstum nach 2030 anNASDAQ:AZNAstraZeneca PLC
21/05/202417h36Business WireAstraZeneca prévoit de réaliser un chiffre d’affaires total de 80 milliards de dollars d’ici 2030 et d’atteindre une croissance continue après 2030NASDAQ:AZNAstraZeneca PLC
21/05/202413h18IH Market NewsCalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More NewsNASDAQ:AZNAstraZeneca PLC
21/05/202408h00Business WireAstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030NASDAQ:AZNAstraZeneca PLC
19/05/202423h17Business WireNew data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary diseaseNASDAQ:AZNAstraZeneca PLC
13/05/202413h16IH Market NewsArm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and MoreNASDAQ:AZNAstraZeneca PLC
06/05/202408h00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaNASDAQ:AZNAstraZeneca PLC
02/05/202413h00Business WireCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trialNASDAQ:AZNAstraZeneca PLC
01/05/202413h05Business WireAstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolioNASDAQ:AZNAstraZeneca PLC
29/04/202413h00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralowNASDAQ:AZNAstraZeneca PLC
25/04/202414h00PR Newswire (US)AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:AZNAstraZeneca PLC
25/04/202413h53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Dernières Valeurs Consultées

NASDAQ
MSFT
Microsoft
SPI
SP500
S&P 500
EU
RI
Pernod Ricard
NASDAQ
NVDA
NVIDIA
EU
HO
Thales
NYSE
MCD
McDonalds
EU
VIV
Vivendi
EU
VK
Vallourec
NASDAQ
AAPL
Apple
EU
GLE
Societe Generale
COIN
ETHUSD
Ethereum
EU
EN
Bouygues
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés